Telehouse Canada Announces Leadership Transition as It Enters Its Next Phase of Growth
1.4.2025 12:37:00 CEST | Business Wire | Press Release
Telehouse Canada, a leading colocation data centre service provider, has appointed Atsushi Kubo as the new President & Chief Executive Officer with immediate effect.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250401440358/en/
Atsushi Kubo, President & Chief Executive Officer
Atsushi Kubo, formerly Executive Vice President and Chief Operating Officer, brings extensive experience in business strategy and operational execution, joining Telehouse Canada in 2023 from parent company KDDI, a Japanese telecommunications provider. Prior to this, Kubo spent four years at Telehouse Europe as Head of Product and Business Development, where he played a key role in strategic business operations, leading product strategy and expansion. Kubo’s expertise in global data centre management was instrumental in identifying and leading the acquisition that positioned Telehouse Canada for long-term success. Over the past year, he has overseen the execution of the company’s business plan while managing daily operations as a senior leader. In his new role, Kubo will lead the company’s ongoing expansion plans and new growth initiatives, ensuring continued excellence in connectivity and data centre services.
"I am honoured to step into this role and to have the opportunity to lead a dynamic team dedicated to delivering premier solutions and services to the Canadian market. As we continue to innovate and grow to meet sector demands, our priority will be ensuring Canadian businesses can leverage the benefits of superior colocation and best-in-class connectivity services," said Atsushi Kubo, President & CEO of Telehouse Canada.
Telehouse Canada operates three carrier-neutral data centres in downtown Toronto that act as a central hub for internet service providers (ISPs), application service providers (ASPs) and Canada’s largest telecommunication carrier networks. Under Satoshi Adachi’s leadership, the company successfully transitioned to KDDI ownership, expanding its operations and strengthening its industry position. As Telehouse Canada embarks on its next phase of growth, Kubo’s appointment as President & CEO marks a pivotal moment for the KDDI subsidiary, which is uniquely positioned to play a critical role in supporting Canadian businesses in the evolving digital landscape.
“It has been a privilege to lead Telehouse Canada during this period of transformation and growth,” said Satoshi Adachi. “I am confident that under Kubo’s leadership, the company will continue to strengthen its position in Canada’s data centre and connectivity landscape.”
About Telehouse
Telehouse is a leading global data centre service provider under KDDI group, bringing together more than 3,000 business partners including carriers, mobile and content providers, enterprises, cloud providers and financial services companies. Established in 1989, Telehouse provides reliable, secure, and flexible colocation, enabling organizations to accelerate speed to market and create business opportunities through fast, efficient and secure interconnections. For more information visit: telehouse.ca
View source version on businesswire.com: https://www.businesswire.com/news/home/20250401440358/en/
Contacts
Media Contact:
Michaela Mason
416-768-6249 | michaela.mason@kaiserpartners.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press Release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press Release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press Release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press Release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press Release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom